{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:41:07Z","timestamp":1790286067707,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Istanbul University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      Vancomycin therapeutic drug monitoring is essential for optimizing efficacy and reducing the risk of vancomycin-associated acute kidney injury (VA-AKI). Although recent guidelines recommend the ratio of area under the curve over 24\u00a0h to minimum inhibitory concentration (AUC\n                      <jats:sub>24<\/jats:sub>\n                      \/MIC)\u2013based monitoring over trough concentration-based monitoring, differences between AUC\n                      <jats:sub>24<\/jats:sub>\n                      \/MIC estimation methods (e.g., pharmacokinetic equations and Bayesian approaches) may influence therapeutic classification in clinical practice. In addition, pharmacogenetic factors contributing to interindividual variability in vancomycin exposure remain incompletely characterized.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This prospective, single-center cohort study included adult patients who received intravenous vancomycin for at least 72\u00a0h between June 2024 and April 2025. Vancomycin trough and peak plasma concentrations were measured using an enzyme-linked immunosorbent assay. AUC\n                      <jats:sub>24<\/jats:sub>\n                      \/MIC values were calculated using pharmacokinetic equation and Bayesian method. Agreement in therapeutic classification between trough concentration\u2013based and AUC\n                      <jats:sub>24<\/jats:sub>\n                      \/MIC-based monitoring was assessed. Associations between the rs2789047 genetic variant and relevant parameters were also evaluated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Thirty-six patients were included, of whom 38.9% developed VA-AKI. Despite strong correlations between trough concentration and AUC\n                      <jats:sub>24<\/jats:sub>\n                      \/MIC values (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.84\u20130.87), substantial discordance in therapeutic classification was observed, with agreement rates of 63.9% for pharmacokinetic equation-based and 66.7% for Bayesian-based compared with trough concentration-based monitoring. In contrast, pharmacokinetic equation-based and Bayesian-based methods demonstrated strong concordance (86.1%). Higher trough concentrations and AUC\n                      <jats:sub>24<\/jats:sub>\n                      \/MIC values were significantly associated with VA-AKI (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Carriers of rs2789047 A-allele exhibited higher trough concentrations and reduced elimination rates.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Trough concentration-based monitoring frequently misclassified vancomycin exposure compared with AUC\n                      <jats:sub>24<\/jats:sub>\n                      \/MIC\u2013based approaches. Pharmacogenetic variability may further influence vancomycin exposure.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00228-026-04103-w","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T01:34:31Z","timestamp":1781746471000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of Vancomycin Therapeutic Drug Monitoring Strategies: Pharmacokinetic, Pharmacogenetic, and Clinical Perspectives in a Prospective, Real-World Cohort Study"],"prefix":"10.1007","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4932-4183","authenticated-orcid":false,"given":"\u0130lker","family":"Kurt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5714-031X","authenticated-orcid":false,"given":"Esen G\u00fcl","family":"Ko\u00e7ak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3388-0927","authenticated-orcid":false,"given":"Meliha","family":"\u015een","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9091-6087","authenticated-orcid":false,"given":"Bilg\u00fcl","family":"Mete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6915-9843","authenticated-orcid":false,"given":"G\u00f6khan","family":"Ayg\u00fcn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2647-6416","authenticated-orcid":false,"given":"\u00d6zkan","family":"\u00d6zdemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4628-8391","authenticated-orcid":false,"given":"Mehmet G\u00fcven","family":"G\u00fcnver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3122-5099","authenticated-orcid":false,"given":"Yal\u0131m","family":"Dikmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8632-2825","authenticated-orcid":false,"given":"\u00d6mer Fehmi","family":"Tabak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6729-8150","authenticated-orcid":false,"given":"B. S\u00f6nmez","family":"Uyde\u015f Do\u011fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7898-5602","authenticated-orcid":false,"given":"Zeliha","family":"Pala Kara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"4103_CR1","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","volume":"77","author":"MJ Rybak","year":"2020","unstructured":"Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C et al (2020) Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health-System Pharm 77:835\u2013864. https:\/\/doi.org\/10.1093\/ajhp\/zxaa036","journal-title":"Am J Health-System Pharm"},{"key":"4103_CR2","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1097\/FTD.0000000000000944","volume":"44","author":"SE Reuter","year":"2022","unstructured":"Reuter SE, Stocker SL, Alffenaar JWC, Baldelli S, Cattaneo D, Jones G et al (2022) Optimal practice for vancomycin therapeutic drug monitoring: Position statement from the anti-infectives committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Ther Drug Monit 44:121\u2013132. https:\/\/doi.org\/10.1097\/FTD.0000000000000944","journal-title":"Ther Drug Monit"},{"key":"4103_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.5005\/jp-journals-10081-1387","volume":"5","author":"B Shenoy","year":"2023","unstructured":"Shenoy B, Joshi DN, Doddikoppad P (2023) Vancomycin therapeutic drug monitoring. Pediatr Infect Dis 5:17\u201319. https:\/\/doi.org\/10.5005\/jp-journals-10081-1387","journal-title":"Pediatr Infect Dis"},{"key":"4103_CR4","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1086\/600877","volume":"49","author":"MJ Rybak","year":"2009","unstructured":"Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC Jr, Craig WA, Billeter M et al (2009) Vancomycin therapeutic guidelines: A summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 49:325\u2013327. https:\/\/doi.org\/10.1086\/600877","journal-title":"Clin Infect Dis"},{"key":"4103_CR5","doi-asserted-by":"publisher","unstructured":"Marko R, Hajjar J, Nzeribe V, Pittman M, Deslandes V, Sant N et al (2021) Therapeutic drug monitoring of vancomycin in adult patients with methicillin-resistant Staphylococcus aureus bacteremia or pneumonia. Can J Hosp Pharm 74. https:\/\/doi.org\/10.4212\/cjhp.v74i4.3195","DOI":"10.4212\/cjhp.v74i4.3195"},{"key":"4103_CR6","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1177\/10600280221141402","volume":"57","author":"J Cerenzio","year":"2023","unstructured":"Cerenzio J, Truong J (2023) Efficacy and safety of vancomycin Bayesian estimated area under the curve versus trough-based dosing. Ann Pharmacother 57:931\u2013939. https:\/\/doi.org\/10.1177\/10600280221141402","journal-title":"Ann Pharmacother"},{"key":"4103_CR7","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1111\/bcp.15301","volume":"89","author":"P Kunming","year":"2023","unstructured":"Kunming P, Xiaotian J, Qing X, Chenqi X, Xiaoqiang D, Qianzhou L (2023) Impact of pharmacist intervention in reducing vancomycin-associated acute kidney injury: a systematic review and meta-analysis. Br J Clin Pharmacol 89:526\u2013535. https:\/\/doi.org\/10.1111\/bcp.15301","journal-title":"Br J Clin Pharmacol"},{"key":"4103_CR8","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2147\/PGPM.S167886","volume":"12","author":"S Jeibouei","year":"2019","unstructured":"Jeibouei S, Akbari ME, Kalbasi A, Aref AR, Ajoudanian M et al (2019) Personalized medicine in breast cancer: Pharmacogenomics approaches. Pharmgenomics Pers Med 12:59\u201373. https:\/\/doi.org\/10.2147\/PGPM.S167886","journal-title":"Pharmgenomics Pers Med"},{"key":"4103_CR9","doi-asserted-by":"publisher","first-page":"e0127791","DOI":"10.1371\/journal.pone.0127791","volume":"10","author":"SL Van Driest","year":"2015","unstructured":"Van Driest SL, McGregor TL, Velez Edwards DR, Saville BR, Kitchner TE, Hebbring SJ et al (2015) Genome-wide association study of serum creatinine levels during vancomycin therapy. PLoS ONE 10:e0127791. https:\/\/doi.org\/10.1371\/journal.pone.0127791","journal-title":"PLoS ONE"},{"key":"4103_CR10","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1002\/phar.2722","volume":"42","author":"E Abdelmessih","year":"2022","unstructured":"Abdelmessih E, Patel N, Vekaria J, Crovetto B, SanFilippo S, Adams C, Brunetti L (2022) Vancomycin area under the curve versus trough-only guided dosing and the risk of acute kidney injury: systematic review and meta-analysis. Pharmacotherapy 42:741\u2013753. https:\/\/doi.org\/10.1002\/phar.2722","journal-title":"Pharmacotherapy"},{"key":"4103_CR11","doi-asserted-by":"publisher","DOI":"10.1177\/08971900241287274","author":"KLT Johnson-Louis","year":"2025","unstructured":"Johnson-Louis KLT, Nguyen ML, Zvonar RK (2025) A comparison of vancomycin area under the curve and trough concentration in specific populations. J Pharm Pract 38(3):305-313.\u00a0https:\/\/doi.org\/10.1177\/08971900241287274","journal-title":"J Pharm Pract"},{"key":"4103_CR12","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/phar.2670","volume":"42","author":"KB Olney","year":"2022","unstructured":"Olney KB, Wallace KL, Mynatt RP, Burgess DS, Grieves K, Willett A, Mani J, Flannery AH (2022) Comparison of Bayesian-derived and first-order analytic equations for calculation of vancomycin area under the curve. Pharmacotherapy 42:284\u2013291. https:\/\/doi.org\/10.1002\/phar.2670","journal-title":"Pharmacotherapy"},{"key":"4103_CR13","doi-asserted-by":"publisher","DOI":"10.1177\/20499361221140368","volume":"9","author":"M Chen","year":"2022","unstructured":"Chen M, Lee C, Gnyra M, Wong M (2022) Vancomycin area under the curve\/minimum inhibitory concentration and trough level concordance\u2013evaluation on an urban health unit. Ther Adv Infect Dis 9:20499361221140368. https:\/\/doi.org\/10.1177\/20499361221140368","journal-title":"Ther Adv Infect Dis"},{"key":"4103_CR14","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1097\/FTD.0000000000000622","volume":"41","author":"L Clark","year":"2019","unstructured":"Clark L, Skrupky LP, Servais R, Brummitt CF, Dilworth TJ (2019) Examining the relationship between vancomycin area under the concentration\u2013time curve and serum trough levels in adults with presumed or documented staphylococcal infections. Ther Drug Monit 41:483\u2013488. https:\/\/doi.org\/10.1097\/FTD.0000000000000622","journal-title":"Ther Drug Monit"},{"key":"4103_CR15","doi-asserted-by":"publisher","first-page":"201","DOI":"10.34172\/PS.2020.70","volume":"27","author":"A Esmaeili","year":"2021","unstructured":"Esmaeili A, Salehi M, Makhdoomi N, Ardakani YH, Rajabi M, Namazi S (2021) Evaluation of the association between trough and area under the curve to minimum inhibitory concentration ratio (AUC24\/MIC) of vancomycin in infected patients with methicillin-resistant Staphylococcus aureus. Pharm Sci 27:201\u2013208. https:\/\/doi.org\/10.34172\/PS.2020.70","journal-title":"Pharm Sci"},{"key":"4103_CR16","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaf041","author":"J Shiau","year":"2025","unstructured":"Shiau J, Roy S, Sabourenkov P, Scheetz MH (2025) Big data Bayesian truths: no vancomycin trough concentration target is sufficiently precise for safety or efficacy. Open Forum Infect Dis 12(3).\u00a0https:\/\/doi.org\/10.1093\/ofid\/ofaf041","journal-title":"Open Forum Infect Dis"},{"key":"4103_CR17","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1097\/FTD.0000000000000359","volume":"39","author":"A Bel Kamel","year":"2017","unstructured":"Bel Kamel A, Bourguignon L, Marcos M, Ducher M, Goutelle S (2017) Is trough concentration of vancomycin predictive of the area under the curve? A clinical study in elderly patients. Ther Drug Monit 39:83\u201387. https:\/\/doi.org\/10.1097\/FTD.0000000000000359","journal-title":"Ther Drug Monit"},{"key":"4103_CR18","doi-asserted-by":"publisher","first-page":"408","DOI":"10.32429\/jkshp.2020.37.4.001","volume":"37","author":"YM Sohn","year":"2020","unstructured":"Sohn YM, Park HJ, Chung JE, Huh K, Jeon K, Lee YS, Min MS (2020) Low correlation between vancomycin area under the curve over 24 hours to the minimum inhibitory concentration ratio and the trough concentration at steady state in methicillin-resistant Staphylococcus aureus pneumonia. J Korean Soc Health-Syst Pharm 37:408\u2013416. https:\/\/doi.org\/10.32429\/jkshp.2020.37.4.001","journal-title":"J Korean Soc Health-Syst Pharm"},{"key":"4103_CR19","doi-asserted-by":"publisher","first-page":"3977","DOI":"10.1111\/bcp.15429","volume":"88","author":"JY Kim","year":"2022","unstructured":"Kim JY, Yee J, Yoon HY, Han JM, Gwak HS (2022) Risk factors for vancomycin-associated acute kidney injury: a systematic review and meta-analysis. Br J Clin Pharmacol 88:3977\u20133989. https:\/\/doi.org\/10.1111\/bcp.15429","journal-title":"Br J Clin Pharmacol"},{"key":"4103_CR20","doi-asserted-by":"publisher","first-page":"920","DOI":"10.3390\/antibiotics9120920","volume":"9","author":"T Miyai","year":"2020","unstructured":"Miyai T, Imai S, Kashiwagi H, Sato Y, Kadomura S, Yoshida K et al (2020) A risk prediction flowchart of vancomycin-induced acute kidney injury to use when starting vancomycin administration: A multicenter retrospective study. Antibiotics 9:920. https:\/\/doi.org\/10.3390\/antibiotics9120920","journal-title":"Antibiotics"},{"key":"4103_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.632107","author":"P Kunming","year":"2021","unstructured":"Kunming P, Can C, Zhangzhang C, Wei W, Qing X, Xiaoqiang D, Xiaoyu L, Qianzhou L (2021) Vancomycin-associated acute kidney injury: a longitudinal study in China. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2021.632107","journal-title":"Front Pharmacol"},{"key":"4103_CR22","first-page":"22","volume":"32","author":"J Barber\u00e1n","year":"2019","unstructured":"Barber\u00e1n J, Mensa J, Artero A, Epelde F, Rodriguez JC, Ruiz-Morales J, Calleja JL, Guerra JM, Mart\u00ednez-Gil I, Gim\u00e9nez MJ, Granizo JJ, Aguilar L (2019) Factors associated with development of nephrotoxicity in patients treated with vancomycin versus daptomycin for severe Gram-positive infections: a practice-based study. Rev Esp Quimioter 32:22\u201330","journal-title":"Rev Esp Quimioter"},{"key":"4103_CR23","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/cts.12731","volume":"13","author":"C Pan","year":"2020","unstructured":"Pan C, Wen A, Li X, Li D, Zhang Y, Liao Y, Ren Y, Shen S (2020) Development and validation of a risk prediction model of vancomycin-associated nephrotoxicity in elderly patients: a pilot study. Clin Transl Sci 13:491\u2013497. https:\/\/doi.org\/10.1111\/cts.12731","journal-title":"Clin Transl Sci"},{"key":"4103_CR24","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1093\/cid\/ciz051","volume":"69","author":"DM Aljefri","year":"2019","unstructured":"Aljefri DM, Avedissian SN, Rhodes NJ, Postelnick MJ, Nguyen K, Scheetz MH (2019) Vancomycin area under the curve and acute kidney injury: a meta-analysis. Clin Infect Dis 69:1881\u20131887. https:\/\/doi.org\/10.1093\/cid\/ciz051","journal-title":"Clin Infect Dis"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04103-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04103-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04103-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T07:57:34Z","timestamp":1783929454000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-026-04103-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["4103"],"URL":"https:\/\/doi.org\/10.1007\/s00228-026-04103-w","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"assertion":[{"value":"2 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Clinical Research Ethics Committee of Istanbul University-Cerrahpa\u015fa (Approval No. 694, dated May 14, 2024). Written informed consent was obtained from all participants prior to their inclusion in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"178"}}